The present work showed that incorporation of hydrophilic polymer into hydrophobic matrix system can be successfully done in order to model ocular inserts of Brimonidine Tartrate and Timolol providing promising controlled release delivery system. The control of IOP, systemic absorption and hence possible side effects using inserts was found to be better than conventional eye drops. Thus, on the basis of in-vivo anti-glaucoma activity, ocular safety test and stability studies, it can be concluded that this ocular insert can be a promising once-a-day controlled release formulation after due considerations of human in vivo studies.
Cite this article:
R. Z. Mujoriya, M. D. Kshirsagar. Evaluation Study of Sustained Release Ocular Insert of Brimonidine Tartrate and Timolol. Res. J. Pharm. Dosage Form. & Tech. 2016; 8(4): 231-236. doi: 10.5958/0975-4377.2016.00032.X